Ockert D, Schirrmacher V, Beck N, Stoelben E, Ahlert T, Flechtenmacher J, Hagmüller E, Buchcik R, Nagel M, Saeger H D
Surgical Department, University Hospital, Mannheim, Gynecology Department, University Hospital, Heidelberg, Germany.
Clin Cancer Res. 1996 Jan;2(1):21-8.
An active specific immunization (ASI) procedure with two types of autologous tumor cell vaccines (ATVs) is tested for adjuvant immunotherapy of resected colorectal carcinoma to provide preliminary information on local immunological skin responses, side effects, and 2-year survival rates. For vaccine preparation, the tumor-derived freshly isolated and cryopreserved cells were thawed, purified by Percoll density centrifugation, and depleted of tumor-infiltrating lymphocytes by immunomagnetic beads. After inactivation by 200 Gy, the cells of this ATV were either infected by Newcastle disease virus (NDV) or they were admixed with Bacillus Calmette Guérin (BCG) organisms. Vaccination was performed in the arm beginning 6-8 weeks after operation, three times at 2-week intervals. Of 57 patients that received ASI, 48 were treated by virus-infected ATV (ATV-NDV) and 9 were treated with the BCG-admixed vaccine (ATV/BCG). The mean value of delayed hypersensitivity skin reactions from ATV-NDV-treated patients was 18 mm for the first vaccination and 26 and 29 mm for the succeeding ones. Although the application of ATV-NDV was associated with only mild side effects, the ATV/BCG vaccine led to long-lasting ulcers and to more serious side effects. The 2-year survival rate obtained with ATV-NDV was 97.9%, whereas the survival rate with ATV/BCG was 66.7%. The mean survival of 661 patients from a historical control was 73.8%. These data suggest that the type and quality of the tumor vaccine for ASI treatment is important. The findings with ATV-NDV necessitate corroboration in a prospective, randomized controlled study.
对两种自体肿瘤细胞疫苗（ATV）进行主动特异性免疫（ASI）程序，用于切除的结直肠癌的辅助免疫治疗，以提供有关局部免疫皮肤反应、副作用和2年生存率的初步信息。疫苗制备时，将新鲜分离并冷冻保存的肿瘤来源细胞解冻，通过Percoll密度离心法纯化，并用免疫磁珠去除肿瘤浸润淋巴细胞。经200 Gy灭活后，这种ATV的细胞要么用新城疫病毒（NDV）感染，要么与卡介苗（BCG）混合。术后6 - 8周开始在手臂进行接种，每隔2周接种3次。在接受ASI的57例患者中，48例接受病毒感染的ATV（ATV-NDV）治疗，9例接受卡介苗混合疫苗（ATV/BCG）治疗。接受ATV-NDV治疗的患者首次接种时迟发型超敏皮肤反应的平均值为18 mm，后续接种分别为26 mm和29 mm。虽然应用ATV-NDV仅伴有轻微副作用，但ATV/BCG疫苗导致持久溃疡和更严重的副作用。ATV-NDV的2年生存率为97.9%，而ATV/BCG的生存率为66.7%。历史对照的661例患者的平均生存率为73.8%。这些数据表明，用于ASI治疗的肿瘤疫苗的类型和质量很重要。ATV-NDV的研究结果需要在前瞻性随机对照研究中得到证实。
